arrow
Yutaka Yasui 封面图

Yutaka Yasui

musashino red cross hospitalFaculty邮箱:yutakayas@hotmail.com
H指数:78
被引数:2.5万

个人简介

Received a Bachelor of Engineering in Environmental Engineering from Kyoto University in 1989 and a PhD in Biostatistics from Johns Hopkins School of Public Health in 1994. The scholar worked in the Department of Health Policy and Management, Injury Prevention Center, and Health Services and Development Center at Johns Hopkins in 1994-1995, and then in the Cancer Prevention Research Program at Fred Hutchinson Cancer Center and the Department of Biostatistics at University of Washington in 1995-2004. The scholar joined the Department of Public Health Sciences in November 2004. The scholar’s research is focused on developing and applying biostatistical and epidemiologic methods in the intersection of biology and clinical/public health sciences, especially on quantitative issues in biomarker discovery research.

教育背景

  • 1989.12

    Kyoto University (Japan) Bachelor of Engineering Environmental Engineering

  • 1994.12

    Johns Hopkins School of Public Health (Baltimore, USA) PhD Biostatistics

工作经历

  • 2004.11 – 至今

    Department of Public Health Sciences

    Faculty

  • 2004.01 – 2007.12

    US National Institute of Health

    Regular Member in the Cancer Biomarker Study Section

  • 1995.01 – 2004.12

    Fred Hutchinson Cancer Center and the Department of Biostatistics at University of Washington (Seattle, USA)

    Cancer Prevention Research Program

  • 1994.01 – 1995.12

    Johns Hopkins

    Department of Health Policy and Management, Injury Prevention Center, and Health Services and Development Center

荣誉奖项

  1. Advising, Mentoring, and Teaching Recognition Award(May 1995)|The Student Assembly, School of Hygiene and Public Health, Johns Hopkins University
  2. 1994 Faculty Award for Excellence in Teaching/Advising(May 1995)|Student Coordinating Committee, Department of Health Policy and Management, School of Hygiene and Public Health, Johns Hopkins University
  3. Teaching Award of Excellence(2006-2007, 2008-2009)|Public Health Sciences Student Association, Department of Public Health Sciences, School of Public Health, University of Alberta
Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance Elastography

早期和长期肝脏硬度变化在经系列磁共振弹性成像检查的MASLD患者中的关联

2026-06-160
OAAI
Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver Cirrhosis

血清锌阈值及锌补充对肝硬化预后的影响

2026-05-070
OAAI
Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds

FIB-4指数和FIB-3指数对慢性肝病中晚期肝纤维化的诊断准确性及年龄特异性阈值

2026-03-030
OAAI
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study

基于治疗暴露的风险分层管理儿童癌症幸存者护理:一项来自儿童癌症幸存者研究的研究报告

2025-10-011
PRE
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

不可切除的肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后的三年总生存率

2025-08-280
PRE
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC

血清FGF21作为对atezolizumab和bevacizumab在HCC中反应的预测因子

2025-02-010
OAAI
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy
2024-09-021
PRE
Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma

在不可切除的肝细胞癌中,先前使用免疫检查点抑制剂进展后对durvalumab联合tremelimumab的治疗反应

2024-08-303
PRE
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
2024-06-060
OAAI
Using an mHealth approach to collect patient-generated health data for predicting adverse health outcomes among adult survivors of childhood cancer
2024-05-102
OAAI
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2024-03-175
PRE
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease

代谢功能障碍相关性脂肪性肝病与非酒精性脂肪性肝病的一致性

2024-01-1716
PRE